Ellicott City, Md., July 16, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced that Medidata Solutions, the leading global provider of cloud-based solutions for clinical research in life sciences, has joined SCRS’ Circle of Sustainability Sponsorship program. The program is designed to facilitate critical dialogue between industry stakeholders and clinical research sites, furthering SCRS’ mission of unifying the site community for greater sustainability.
“SCRS is proud to welcome Medidata as a Circle of Sustainability Sponsor,” said Christine Pierre, SCRS President. “The forward momentum of the clinical research industry is contingent upon improved relationships between sites, industry stakeholders, and solution-providers such as Medidata. This high-level partnership is symbolic of Medidata’s deep commitment to creating a more sustainable future for sites globally.”
As part of this program, Medidata’s president Glen de Vries will serve on the SCRS Global Impact Board, working with the organization’s leadership council to determine strategic initiatives for the society. Additionally, Medidata will sponsor and moderate the “Site Tank” session at the 2015 Global Site Solutions Summit in Amelia Island, Florida on October 8-11. During the session, which will take place on October 11 at 10:05 am, representatives from research sites will share innovative ideas on how technology can be used to enhance clinical trial operations.
“Our partnership with SCRS reflects Medidata’s dedication to ensuring research sites have the technology and resources they need to optimize productivity, gather high-quality data and create better patient experiences,” said de Vries. “We’re pleased to support SCRS and the important dialogue the society is facilitating to help the industry move clinical research forward.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.